Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CD22 | P20273 | 12/20 | 0.37 |
| ▸ | MAG | P20916 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13410073 | 1.00 | NANP (0.49) | NANPL3MBTL1CD22MAG | |
| SCHEMBL28733256 | 1.00 | NANP (0.49) | NANPL3MBTL1CD22MAG | |
| SCHEMBL29570167 | 1.00 | NANP (0.49) | NANPL3MBTL1CD22MAG | |
| SCHEMBL6046364 | 0.92 | NANP (0.52) | NANPL3MBTL1CD22MAG | |
| SCHEMBL29696108 | 0.92 | NANP (0.52) | NANPL3MBTL1CD22MAG | |
| SCHEMBL28733252 | 0.92 | NANP (0.52) | NANPL3MBTL1CD22MAG | |
| SCHEMBL6046357 | 0.91 | NANP (0.52) | NANPL3MBTL1CD22MAG | |
| SCHEMBL28733269 | 0.91 | NANP (0.52) | NANPL3MBTL1CD22MAG | |
| SCHEMBL13190998 | 0.91 | NANP (0.59) | NANPL3MBTL1MAG | |
| SCHEMBL6046362 | 0.91 | NANP (0.59) | NANPL3MBTL1MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288095-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | LIFESCIENCE AS (NO) | 2022-09-15 | — | — | US | claimed |
| US-20260083762-A1 | SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION | LIFESCIENCE AS (NO) | 2026-03-26 | — | — | US | disclosed |
| US-12390481-B2 | Sialic acid compositions for the use of inhibiting and treating coronavirus infection | LIFESCIENCE AS (NO) | 2025-08-19 | — | — | US | disclosed |
| EP-4590428-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | Donaldson Company, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250057862-A1 | SIALIC ACID COMPOSITIONS FOR USE IN INHIBITING AND TREATING INFECTIONS IN FISH | LIFESCIENCE AS (NO) | 2025-02-20 | — | — | US | disclosed |
| EP-4447978-A1 | SIALIC ACID COMPOSITIONS FOR USE IN INHIBITING AND TREATING INFECTIONS IN FISH | Lifescience AS (NO) | 2024-10-23 | — | — | EP | disclosed |
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | DONALDSON COMPANY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240148763-A1 | SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION | LIFESCIENCE AS (NO) | 2024-05-09 | — | — | US | disclosed |
| US-20160024125-A1 | NATURAL LIPIDS CONTAINING NON-OXIDIZABLE FATTY ACIDS | BERGEN TEKNOLOGIOVERFØRING AS (NO) | 2016-01-28 | — | — | US | disclosed |
| US-20120282350-A1 | PERFORMANCE ENHANCING COMPOSITIONS AND METHODS OF USE | LIFE SCIENCE NUTRITION AS (NO) | 2012-11-08 | — | — | US | disclosed |
| US-20060218670-A1 | Compositions and methods for production of sialylated glyoproteins in plants | ARIZONA BOARD OF REGENTS, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2006-09-28 | — | — | US | disclosed |
| US-6001819-A | RESPIRATORY SYSTEM DISORDERS | NEOSE TECHNOLOGIES, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0918526-A1 | BISMUTH SALT OF SIALYLOLIGOSACCHARIDE AND A METHOD FOR TREATING AND INHIBITING GASTRIC AND DUODENAL ULCERS WITH SAME | Neose Technologies, Inc. (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0839042-A4 | BACTERIAL INHIBITION WITH AN OLIGOSACCHARIDE COMPOUND | NEOSE TECHNOLOGIES INC (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0839042-A1 | BACTERIAL INHIBITION WITH AN OLIGOSACCHARIDE COMPOUND | Neose Technologies, Inc. (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5736533-A | INHIBITING COLONIZATION OF STREPTOCOCCUS PNEUMONIAE, HEMOPHILUS INFLUENZA OR PARAINFLUENZA, BURKHOLDERIA (PSEUDOMONAS) CEPACIA BY ADMINISTERING BINDING INHIBITING OLIGOSACCHARIDE | NEOSE TECHNOLOGIES, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997041875-A1 | BISMUTH SALT OF SIALYLOLIGOSACCHARIDE AND A METHOD FOR TREATING AND INHIBITING GASTRIC AND DUODENAL ULCERS WITH SAME | NEOSE TECHNOLOGIES, INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1996040169-A1 | BACTERIAL INHIBITION WITH AN OLIGOSACCHARIDE COMPOUND | NEOSE TECHNOLOGIES, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057862-A1 | SIALIC ACID COMPOSITIONS FOR USE IN INHIBITING AND TREATING INFECTIONS IN FISH | SIGLEC9, SIGLEC7, NEU3 | NANP 16/4885L3MBTL1 2053/4885CD22 39/4885 |
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | CACYBP, MGAM, MASP2 | NANP 1105/4885L3MBTL1 2639/4885CD22 633/4885 |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, MASP2, MGAM2 | NANP 282/4885L3MBTL1 4034/4885CD22 186/4885 |
| US-20160024125-A1 | NATURAL LIPIDS CONTAINING NON-OXIDIZABLE FATTY ACIDS | FASN, ELOVL1, FADS1 | NANP 539/4885L3MBTL1 3842/4885CD22 2290/4885 |
| US-20260083762-A1 | SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION | NEU2, NEU1, SIGLEC9 | NANP 32/4885L3MBTL1 4162/4885CD22 96/4885 |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, CA14, MASP2 | NANP 357/4885L3MBTL1 3910/4885CD22 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.